| 摘要 |
The disclosure is directed to methods for treating non-functioning pituitary adenomas with alpha-folate receptor (“FR-α”) and compositions. In some embodiments, the disclosure is directed to a method for treating a pituitary adenoma that includes administering farletuzumab to a subject diagnosed with a non-functioning pituitary adenoma.
|
